WallStreetZenWallStreetZen

NASDAQ: CALC
Calcimedica Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their CALC stock forecasts and price targets.

Forecast return on equity

Is CALC forecast to generate an efficient return?

Forecast return on assets

Is CALC forecast to generate an efficient return on assets?

Company
-258.22%
Industry
27.44%
CALC is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CALC earnings per share forecast

What is CALC's earnings per share in the next 2 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$1.83
Avg 2 year Forecast
-$2.67

CALC revenue forecast

What is CALC's revenue in the next 2 years based on estimates from 6 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$10.2M

CALC vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CALC$0.67N/AN/A
ERNA$1.24N/AN/A
IMNN$3.18N/AN/A
PHGE$6.23$26.00+317.34%Buy
PULM$2.59N/AN/A
View Top Biotech Stocks

Calcimedica Stock Forecast FAQ

What is CALC's earnings growth forecast for 2026-2027?

(NASDAQ: CALC) Calcimedica's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 200.46%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 3,218.89%.

Calcimedica's earnings in 2026 is -$23,060,000.On average, 6 Wall Street analysts forecast CALC's earnings for 2026 to be -$26,308,739, with the lowest CALC earnings forecast at -$30,219,459, and the highest CALC earnings forecast at -$23,602,648.

In 2027, CALC is forecast to generate -$38,507,763 in earnings, with the lowest earnings forecast at -$42,222,515 and the highest earnings forecast at -$34,042,281.

If you're new to stock investing, here's how to buy Calcimedica stock.

What is CALC's revenue growth forecast for 2026-2027?

(NASDAQ: CALC) Calcimedica's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 11,996.93%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,540.38%.

Calcimedica's revenue in 2026 is $0.On average, 6 Wall Street analysts forecast CALC's revenue for 2026 to be $0, with the lowest CALC revenue forecast at $0, and the highest CALC revenue forecast at $0.

In 2027, CALC is forecast to generate $146,976,196 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $302,598,051.

What is CALC's forecast return on assets (ROA) for 2026-2027?

(NASDAQ: CALC) forecast ROA is -258.22%, which is lower than the forecast US Biotechnology industry average of 27.44%.

What is CALC's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: CALC) Calcimedica's current Earnings Per Share (EPS) is -$1.62. On average, analysts forecast that CALC's EPS will be -$1.83 for 2026, with the lowest EPS forecast at -$2.10, and the highest EPS forecast at -$1.64. In 2027, CALC's EPS is forecast to hit -$2.67 (min: -$2.93, max: -$2.36).

What is CALC's forecast return on equity (ROE) for 2026-2027?

(NASDAQ: CALC) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.